MetaCap

Aclaris Therapeutics Inc. (ACRS)

NASDAQ: ACRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.44-0.06 (-1.71%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ACRS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$545.63M
EPS (TTM)
-$0.59
52-week range
2.46 – 6.60
Day range
3.40 – 3.54
Volume / Avg
2.19M / 3.07M
Beta
—

52-week range

$2.46$6.60

ACRS stock today

Shares of Aclaris Therapeutics (ACRS) finished lower on Nov 20 at $3.44, a drop of 1.71% or $0.06 per share, versus the S&P 500's 3.70% decline. Shares are 47.9% below their 52-week high of $6.60, set on Aug 25, 2026 and 39.8% above the 52-week low of $2.46, in the middle of the past year's range. ACRS is up 14.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 37.1%.

Aclaris Therapeutics has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Aclaris Therapeutics

Company profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Neal S. Walker D.O., M.D.
Headquarters
Wayne, PA
Employees
69
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Aclaris Therapeutics generated $7.8 million in revenue, down 58.2% from fiscal 2024, its first annual decline since 2024. Aclaris Therapeutics reported a net loss of $64.9 million, compared with a loss of $132.1 million a year earlier. Gross margin was 73.3% (down from 85.1%) and operating margin -975.9%.

Aclaris Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$7.83M$18.72M$31.25M$29.75M$6.76M
Growth-58.19%-40.09%+5.03%+340.05%+4.30%
Net income$-64.92M$-132.06M$-88.48M$-86.91M$-90.86M
EPS (diluted)$-0.53$-1.71$-1.27$-1.33$-1.60

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$10.50+205.23%

  • Strong buy 1
  • Buy 9
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $16.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.12 vs $-0.16
Surprise
+25.00%

ACRS news

All ACRS news

Aclaris Therapeutics peers

Health Care sector
ACRS peer companies
CompanyPrice% ChgMarket capCompare
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs ACRS
BCAXBicara Therapeutics Inc.8.44-7.46%$560.31Mvs ACRS
GERNGeron Corporation0.8707-4.63%$560.94Mvs ACRS
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs ACRS
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs ACRS
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs ACRS
DSGNDesign Therapeutics Inc.9.02-3.22%$577.61Mvs ACRS
IMMXImmix Biopharma Inc.6.96-1.14%$583.33Mvs ACRS

Indexes, lists and sector

Aclaris Therapeutics stock FAQ

What is Aclaris Therapeutics's stock price today?

ACRS last traded at $3.44 as of Nov 20, 4:00 PM EST, down 1.71% on the day. Prices are delayed at least 15 minutes.

Who is Aclaris Therapeutics's CEO?

Dr. Neal S. Walker D.O., M.D. is the chief executive officer of Aclaris Therapeutics Inc., which has about 69 employees.

What is the ACRS 52-week high?

The 52-week high for ACRS is $6.60 and the 52-week low is $2.46. The stock is currently 47.9% below its high.

Compare ACRS